Traits, trends and hits of orphan drug designations in cystic fibrosis
Enrico Costa(Brigham and Women's Hospital), Hubert G. M. Leufkens(Utrecht University), Hendrika A. van den Ham(Utrecht University), Marco Cipolli(Azienda Ospedaliera Universitaria Integrata Verona), Cornelis K. van der Ent(University Medical Center Utrecht), Jennifer L. Taylor‐Cousar(National Jewish Health), Silvia Girotti(University of Verona)
Cited by 6
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications
|European Journal of Clinical Pharmacology|2014|162
Outrageous prices of orphan drugs: a call for collaboration
|The Lancet|2018|160
Development of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2015|136
Antibiotic prescribing for children in primary care and adherence to treatment guidelines
|Journal of Antimicrobial Chemotherapy|2016|74